Cytokines assets in PLWH in two-drug dolutergravir based or three-drug antiretroviral regimen
- PMID: 38961336
- PMCID: PMC11223302
- DOI: 10.1186/s12879-024-09565-w
Cytokines assets in PLWH in two-drug dolutergravir based or three-drug antiretroviral regimen
Abstract
To minimize the toxicity and impact of combined antiretroviral therapy (cART) on the lifestyle of people living with Human Immunodeficiency Virus (PLWH), scientific community evaluated the efficacy, safety and sustained virologic response of two drugs antiretroviral regimens, in particular dolutegravir (DTG). The effects of deintensification therapy on inflammatory settings are currently unknown in PLWH. Thus, our study explored the inflammatory state in virologically suppressed HIV individuals between patients in treatment with a DTG-containing dual therapy (2DR) versus triple regimen therapies (3DR). We enrolled a total of 116 subjects in 2DRs or 3DRs regimens, and the plasma levels of pro- and anti-inflammatory cytokines (in particular IL-1β, IL-10, IL-18, IL-33, IL-36 and IFN-γ) have been evaluated. CD4 + cell's median value was 729.0 cell/µL in the 3DR group and 771.5 cell/µL in 2DR group; the viral load was negative in all patients. Significant differences were found in levels of IL-18 (648.8 cell/µL in 3DR group vs. 475.0 cell/µL in 2DR group, p = 0.034) and IL-36 (281.7 cell/µL in 3DR group vs. 247.0 cell/µL in 2DR group, p = 0.050), and a correlation between IL-18 and IL-36 was found in 3DR group (rho = 0.266, p = 0.015). This single-center retrospective pharmacological study confirms the absence of significant differences in IL-1β, IL-10, IL-33, and IFN-γ levels between patients on two-drug antiretroviral regimens compared to patients on 3DR antiretroviral regimens. Patients in 2DR show greater control over IL-18 and IL-36 serum levels, cytokines related to an increased cardiovascular risk and development of age-related chronic diseases. Based on our results, we suggest that DTG-based 2DR antiretroviral regimens could be associated with better control of the chronic inflammation that characterizes the population living with HIV in effective ART.
Keywords: 2DRs; 3DR; DTG; HIV; Inflammation.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
The authors have no relevant conflict of interest to disclose.
Figures
Similar articles
-
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States.AIDS Res Ther. 2024 Oct 26;21(1):76. doi: 10.1186/s12981-024-00668-7. AIDS Res Ther. 2024. PMID: 39462377 Free PMC article.
-
Dolutegravir plus lamivudine downregulates cellular stress responses vs. three-drug HIV regimens.AIDS. 2025 Jul 15;39(9):1106-1119. doi: 10.1097/QAD.0000000000004198. Epub 2025 Apr 1. AIDS. 2025. PMID: 40170606 Free PMC article.
-
DTG + 3TC dual therapy for the treatment Naïve patients with viral load exceeding 500,000 copies/mL: a retrospective study.BMC Infect Dis. 2024 Jul 22;24(1):720. doi: 10.1186/s12879-024-09624-2. BMC Infect Dis. 2024. PMID: 39039487 Free PMC article.
-
Dolutegravir plus lamivudine for the treatment of HIV-1 infection.Expert Rev Anti Infect Ther. 2020 Apr;18(4):279-292. doi: 10.1080/14787210.2020.1729742. Epub 2020 Feb 18. Expert Rev Anti Infect Ther. 2020. PMID: 32067525 Review.
-
Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.Ann Pharmacother. 2020 Dec;54(12):1252-1259. doi: 10.1177/1060028020933772. Epub 2020 Jun 9. Ann Pharmacother. 2020. PMID: 32517480 Review.
Cited by
-
INSTIs-centered antiviral regimens for first-line treatment of HIV/AIDS: a network meta-analysis and cost-effectiveness analysis.BMC Infect Dis. 2025 Apr 25;25(1):604. doi: 10.1186/s12879-025-10858-x. BMC Infect Dis. 2025. PMID: 40281525 Free PMC article.
References
-
- Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, Paredes R, Bakowska E, Engsig FN, Phillips A, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013;27(6):973–9. doi: 10.1097/QAD.0b013e32835cae9c. - DOI - PubMed
-
- Sukumaran L, Kunisaki KM, Bakewell N, Winston A, Mallon PWG, Doyle N, Anderson J, Boffito M, Haddow L, Post FA, et al. Association between inflammatory biomarker profiles and cardiovascular risk in individuals with and without HIV. AIDS. 2023;37(4):595–603. doi: 10.1097/QAD.0000000000003462. - DOI - PMC - PubMed
-
- Longenecker CT, Funderburg NT, Jiang Y, Debanne S, Storer N, Labbato DE, Lederman MM, McComsey GA. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med. 2013;14(6):385–90. doi: 10.1111/hiv.12013. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous